Actively Recruiting
Para-aortic Prophylactic Irradiation for Locally Advanced Cervical Cancer
Led by Zhejiang Cancer Hospital · Updated on 2022-01-25
455
Participants Needed
7
Research Sites
469 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Para-aortic lymph node metastasis is a poor prognostic factor for locally advanced cervical cancer, but false negative diagnosis is easy to occur. The aim of this trial was to investigate whether para-aortic prophylactic radiotherapy improves disease-free survival in patients with positive pelvic lymph nodes below the common iliac artery.
CONDITIONS
Official Title
Para-aortic Prophylactic Irradiation for Locally Advanced Cervical Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients voluntarily participate and sign informed consent
- Female aged 18 to 75 years
- Diagnosed with cervical squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma
- FIGO 2009 stage IB2 to IIIA with positive pelvic lymph nodes and negative common iliac and para-aortic nodes by PET-CT
- Eligible for cisplatin chemotherapy
- ECOG performance status 0 or 1
- Expected survival longer than 6 months
- Women of childbearing age must have a negative pregnancy test within 7 days before enrollment and agree to use contraception during the study
- Able to comply with trial protocol as judged by the researcher
You will not qualify if you...
- Uncontrolled severe infections
- Other malignant tumors requiring treatment or newly diagnosed within 5 years
- Prior anti-tumor treatment received
- Liver cirrhosis, decompensated liver disease, chronic kidney failure
- History of immunodeficiency including HIV
- Recent myocardial infarction, severe arrhythmia, or moderate to severe congestive heart failure
- Previous pelvic artery embolization
- Prior pelvic radiotherapy for malignancy
- History of severe allergic reaction to platinum chemotherapy
- Conditions requiring liver or kidney damaging drugs during treatment
- Unable to understand study or unwilling to consent
- Other serious diseases or conditions risking safety or study completion
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 7 locations
1
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China, 310022
Actively Recruiting
2
The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, China
Active, Not Recruiting
3
Jinhua Municipal Central Hospital Medical Group
Jinhua, China
Active, Not Recruiting
4
Lishui People's Hospital
Lishui, China
Active, Not Recruiting
5
Ningbo First Hospital
Ningbo, China
Active, Not Recruiting
6
Taizhou Central Hospiatl
Taizhou, China
Active, Not Recruiting
7
Chongqing University Three Gorges Hospital
Wanzhou, China
Active, Not Recruiting
Research Team
X
Xiang Zhang
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here